Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Artiva Biotherapeutics, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT04673617
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸UF Health Shands Cancer Hospital, Gainesville, Florida, United States
Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT04670068
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
- Conditions
- Diffuse Large B Cell LymphomaCD79B Gene MutationCD79A Gene Mutation
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 59
- Registration Number
- NCT04668365
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 16
- Registration Number
- NCT04667663
- Locations
- 🇮🇪
Beaumont Hospital, Dublin, Ireland
🇮🇪Galway University Hospital, Galway, Ireland
🇮🇪Cork University Hospital, Cork, Ireland
Cabozantinib With Topotecan-Cyclophosphamide
- Conditions
- Relapsed Ewing SarcomaRefractory Ewing SarcomaRelapsed OsteosarcomaRefractory Osteosarcoma
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT04661852
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT04660799
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun City, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳Fujian Provincial Cancer Hospital, Fuzhou City, China
Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 43
- Registration Number
- NCT04659551
- Locations
- 🇮🇹
Arcispedale S. Anna, Cona, FE, Italy
🇮🇹Azienda Ospedaliera Universitaria di Parma, Parma, PR, Italy
🇮🇹Arcispedale S. Maria Nuova, Reggio Emilia, RE, Italy
Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients
- Conditions
- Soft Tissue Sarcoma Adult
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 79
- Registration Number
- NCT04656262
- Locations
- 🇮🇹
Policlinico Sant'Orsola Malpighi, Bologna, BO, Italy
🇮🇹Istituto Clinico Humanitas, Rozzano, MI, Italy
🇮🇹Istituto Ortopedico Rizzoli IRCCS, Bologna, Italy
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
- Conditions
- Refractory B Cell Acute Lymphoblastic Leukemia (ALL)Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Biological: CD19 CAR engineered autologous T-cellsDrug: CyclophosphamideDrug: FludarabineDrug: Mesna
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Sabz Biomedicals
- Target Recruit Count
- 22
- Registration Number
- NCT04653493
- Locations
- 🇮🇷
Gene therapy research center, Shariati hospital, Tehran university of medical sciences, Iran, Tehran, Iran, Islamic Republic of
🇮🇷Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
CAR-T Cells for HIV Infection
- Conditions
- HIV Infections
- Interventions
- Biological: LVgp120duoCAR-T cells, low doseDrug: CyclophosphamideBiological: LVgp120duoCAR-T cells, high doseOther: Analytic Treatment Interruption
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Steven Deeks
- Target Recruit Count
- 18
- Registration Number
- NCT04648046
- Locations
- 🇺🇸
Zuckerberg San Francisco General, San Francisco, California, United States
🇺🇸University of California, Davis, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.